Microhealth
Rare Disease-Focused Care Delivery and Evidence Generation Platform
About
* Category leading RWE platform generating differentiated data through combination of a provider community and patient-reported outcomes; delivering personalized and comparative evidence at the point of care
* Singular network architecture and data capturing capabilities help identify patients with unmet needs in real-time; unlocking opportunities to improve health outcomes and additional revenue for pharma
* Microhealth has achieved product-market fit in the hemophilia and rare blood disorders space
Today, we are the world's leader in digital hematology:
- Our US hemophilia network covers 33%+ of patients on prophylaxis and 50%+ of hemophilia treatment centers - Average active-user retention is 52 months - Trusted by leading pharmaceutical sponsors: Novo Nordisk, Sanofi, Roche and Pfizer
Topics
- Location
- Claymont, DE, United States
- Team size
- 25 employees
- YC batch
- Summer 2015
- Status
- Active
- Stage
- Early stage
